AU2006300951A1 - Antibody polypeptide library screening and selected antibody polypeptides - Google Patents
Antibody polypeptide library screening and selected antibody polypeptides Download PDFInfo
- Publication number
- AU2006300951A1 AU2006300951A1 AU2006300951A AU2006300951A AU2006300951A1 AU 2006300951 A1 AU2006300951 A1 AU 2006300951A1 AU 2006300951 A AU2006300951 A AU 2006300951A AU 2006300951 A AU2006300951 A AU 2006300951A AU 2006300951 A1 AU2006300951 A1 AU 2006300951A1
- Authority
- AU
- Australia
- Prior art keywords
- antibody
- variable domain
- chain variable
- light chain
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0520644.6 | 2005-10-11 | ||
| GB0520644A GB0520644D0 (en) | 2005-10-11 | 2005-10-11 | Antibody polypeptide library screening and selected antibody polypeptides |
| GB0521140.4 | 2005-10-18 | ||
| GB0521140A GB0521140D0 (en) | 2005-10-18 | 2005-10-18 | Antibody polypeptide library screening and selected antibody polypeptides |
| PCT/GB2006/003781 WO2007042809A2 (en) | 2005-10-11 | 2006-10-11 | Antibody polypeptide library screening and selected antibody polypeptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2006300951A1 true AU2006300951A1 (en) | 2007-04-19 |
Family
ID=37943170
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2006300951A Abandoned AU2006300951A1 (en) | 2005-10-11 | 2006-10-11 | Antibody polypeptide library screening and selected antibody polypeptides |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20100168393A1 (https=) |
| EP (1) | EP1951754A2 (https=) |
| JP (1) | JP2009511892A (https=) |
| AU (1) | AU2006300951A1 (https=) |
| CA (1) | CA2625222A1 (https=) |
| WO (1) | WO2007042809A2 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2390425T3 (es) | 2000-12-22 | 2012-11-12 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Uso de moléculas de orientación repulsivas (RGM) y sus moduladores |
| CN101277974A (zh) | 2005-09-30 | 2008-10-01 | 阿伯特有限及两合公司 | 排斥性引导分子(rgm)蛋白质家族的蛋白质的结合结构域及其功能性片段和它们的用途 |
| US8962803B2 (en) | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
| CN104004094B (zh) * | 2008-06-25 | 2017-09-22 | 艾斯巴技术-诺华有限责任公司 | 使用通用抗体构架进行的兔抗体的人源化 |
| MX345039B (es) | 2008-06-25 | 2017-01-16 | Esbatech Alcon Biomed Res Unit | Anticuerpos estables y solubles que inhiben el tnfa. |
| AU2020201002B2 (en) * | 2008-06-25 | 2022-04-07 | Novartis Ag | Humanization of rabbit antibodies using a universal antibody framework |
| CN102656190A (zh) | 2009-12-08 | 2012-09-05 | 雅培股份有限两合公司 | 用于在视网膜神经纤维层变性治疗中使用的针对rgm a蛋白质的单克隆抗体 |
| US8883985B2 (en) | 2010-02-16 | 2014-11-11 | National University Corporation Kyoto Institute Of Technology | Antibody-immobilized carrier, method of producing antibody-immobilized carrier, and use of said antibody-immobilized carrier |
| PL2606064T3 (pl) * | 2010-08-16 | 2015-07-31 | Novimmune Sa | Sposoby wytwarzania wieloswoistych i wielowartościowych przeciwciał |
| AR083495A1 (es) | 2010-10-22 | 2013-02-27 | Esbatech Alcon Biomed Res Unit | Anticuerpos estables y solubles |
| WO2012105833A1 (en) * | 2011-02-01 | 2012-08-09 | Bac Ip B.V. | Antigen-binding protein directed against epitope in the ch1 domain of human igg antibodies |
| NZ714482A (en) | 2012-01-27 | 2017-08-25 | Abbvie Inc | Composition and method for diagnosis and treatment of diseases associated with neurite degeneration |
| CN107814845B (zh) * | 2016-09-14 | 2021-02-09 | 浙江特瑞思药业股份有限公司 | 新的抗pd-1纳米抗体及其应用 |
| CN107857816B (zh) * | 2017-10-17 | 2020-11-06 | 北京大学 | 一种抗干扰素α-2b纳米抗体及其应用 |
| EP3737692A4 (en) | 2018-01-09 | 2021-09-29 | Elstar Therapeutics, Inc. | CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES |
| US12152073B2 (en) | 2018-03-14 | 2024-11-26 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| EP3818083A2 (en) | 2018-07-03 | 2021-05-12 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| GB2595980B (en) * | 2019-01-04 | 2023-06-14 | Marengo Therapeutics Inc | Anti-TCR antibody molecules and uses thereof |
| JP7710373B2 (ja) | 2019-02-21 | 2025-07-18 | マレンゴ・セラピューティクス,インコーポレーテッド | T細胞関連のがん細胞に結合する多機能性分子およびその使用 |
| AU2020224681A1 (en) | 2019-02-21 | 2021-09-16 | Marengo Therapeutics, Inc. | Antibody molecules that bind to NKp30 and uses thereof |
| CN116234829A (zh) | 2020-01-03 | 2023-06-06 | 马伦戈治疗公司 | 抗tcr抗体分子及其用途 |
| EP4341298A4 (en) * | 2021-06-22 | 2025-04-16 | University of Virginia Patent Foundation | COMPOSITIONS AND METHODS FOR DETECTING AND REGULATING FIBRONECTIN-INTEGRIN INTERACTIONS AND SIGNALING |
| CN114195891B (zh) * | 2021-12-22 | 2023-05-12 | 北京世纪沃德生物科技有限公司 | 一种crp驼源单域抗体及其制备方法和应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2136092T3 (es) * | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| GB9722131D0 (en) * | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| ZA9811162B (en) * | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
| US20060252028A1 (en) * | 2002-08-16 | 2006-11-09 | Hiroshi Ueda | Method of assaying interaction between proteins |
| WO2004065611A1 (ja) * | 2003-01-21 | 2004-08-05 | Chugai Seiyaku Kabushiki Kaisha | 抗体の軽鎖スクリーニング方法 |
| EP1711527A4 (en) * | 2003-12-15 | 2008-09-03 | Dendreon Corp | HLA-DR SPECIFIC ANTIBODIES, COMPOSITIONS AND METHODS |
-
2006
- 2006-10-11 WO PCT/GB2006/003781 patent/WO2007042809A2/en not_active Ceased
- 2006-10-11 US US12/083,368 patent/US20100168393A1/en not_active Abandoned
- 2006-10-11 CA CA002625222A patent/CA2625222A1/en not_active Abandoned
- 2006-10-11 EP EP06794731A patent/EP1951754A2/en not_active Withdrawn
- 2006-10-11 AU AU2006300951A patent/AU2006300951A1/en not_active Abandoned
- 2006-10-11 JP JP2008535094A patent/JP2009511892A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2009511892A (ja) | 2009-03-19 |
| EP1951754A2 (en) | 2008-08-06 |
| US20100168393A1 (en) | 2010-07-01 |
| WO2007042809A3 (en) | 2007-07-19 |
| CA2625222A1 (en) | 2007-04-19 |
| WO2007042809A2 (en) | 2007-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20100168393A1 (en) | Antibody Polypeptide Libray Screening and Selected Antibody Polypeptides | |
| AU2005291017B2 (en) | Single domain antibodies against TNFRl and methods of use therefor | |
| AU2003244817B2 (en) | Antigen-binding immunoglobulin single variable domains and dual-specific constructs | |
| AU2008212682B2 (en) | Antibody single variable domains against serum albumin | |
| RU2401842C2 (ru) | Антагонисты и способы их применения | |
| US20060257406A1 (en) | Ligand | |
| JP5901517B2 (ja) | 抗原結合性タンパク質 | |
| JP2012518398A (ja) | 抗原結合性構築物 | |
| US20080233130A1 (en) | Ligand that has binding specificity for IL-4 and/or IL-13 | |
| US9028822B2 (en) | Antagonists against TNFR1 and methods of use therefor | |
| JP2009504686A (ja) | 新世界霊長類領域を用いるキメラ抗体 | |
| US20080008713A1 (en) | Single domain antibodies against tnfr1 and methods of use therefor | |
| CN101084014A (zh) | 抗肿瘤坏死因子受体1的单域抗体及其使用方法 | |
| CN101312988A (zh) | 抗体多肽文库筛选和选择的抗体多肽类 | |
| JP2012518399A (ja) | 抗原結合性構築物 | |
| US20110223168A1 (en) | Ligand that has binding specificity for il-4 and/or il-13 | |
| AU2013273775A1 (en) | Antibody single variable domains against serum albumin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |